FDA bets on AI and cloud monitoring for clinical trials as it looks to rebuild after DOGE layoffs

2026-04-30 · Source: The Decoder · Field: Health & Wellbeing — Healthcare Systems & Policy, Pharmaceuticals & Biotechnology · Depth: Fundamental Awareness, quick

Summary

The U.S. Food and Drug Administration (FDA) is launching a pilot program with AstraZeneca and Amgen to implement real-time monitoring of clinical trials using AI and cloud computing. This initiative aims to replace traditional, lengthy document submissions with direct data feeds, potentially reducing drug approval times by 20 to 40 percent from the current 10-12 years. FDA Commissioner Marty Makary highlighted that approximately 45 percent of the time between the first clinical phase and regulatory submission is spent on administrative tasks. The agency also reports that over 80 percent of its staff now utilize an internal AI tool named Elsa for administrative tasks, significantly speeding up workflows, though concerns about Elsa fabricating studies have been noted.

Key takeaway

For pharmaceutical executives and regulatory affairs teams aiming to accelerate drug development, this FDA pilot signals a shift towards real-time, data-driven oversight. You should explore integrating AI and cloud solutions for direct data feeds from your clinical trials to align with evolving regulatory expectations and potentially reduce market entry timelines. Be mindful of AI tool limitations, such as hallucination, when deploying for critical tasks.

Key insights

Real-time AI and cloud monitoring of clinical trials can significantly accelerate drug approval processes.

Principles

• Direct data feeds reduce administrative overhead.
• AI tools can enhance staff productivity.

Method

The FDA's pilot program involves direct data feeds from ongoing clinical trials to regulators via AI and cloud infrastructure, enabling real-time oversight of patient data and study progress.

In practice

• Implement real-time data streaming for regulatory submissions.
• Utilize internal AI tools for administrative task automation.

Topics

• FDA
• Clinical Trials
• AI Monitoring
• Cloud Computing
• Drug Approval Process

Best for: CTO, Executive, Entrepreneur, Policy Maker, Director of AI/ML, AI Ethicist

Related on AIssential

• FDA Turns to AI to Speed Up Clinical Trials — The FDA is using AI to accelerate clinical trials by streamlining data collection and submission.
• Healthcare Pioneers and Their Breakthroughs for a Healthier Future — AI is rapidly transforming healthcare by accelerating discovery, drug design, and clinical support.
• Breaking: When dreams for AI sanity come true — Government oversight for commercially impactful AI models is gaining traction, mirroring drug approval processes.
• AI-Powered Tools in the Operating Room Is Probably a Bad Idea — Integrating AI into medical devices can introduce significant reliability and safety challenges, as evidenced by increased malfunction reports.
• A randomized controlled trial of artificial intelligence-based analytics for clinical deterioration — Passive AI-based predictive analytics displays did not significantly improve patient outcomes in a clinical trial.
• From Overwhelm to Working AI in Pharma and Life Sciences - with Art Shectman of Elephant Ventures — In highly regulated pharma, prioritize small, agreed-upon workflow slices for rapid, contained AI deployment to build momentum and achieve near-term ROI.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by The Decoder.